Are you a parent of a child with glucose 6 phosphate dehydrogenase (G6PD) deficiency? Are you worried about the potential risks associated with acute kidney injury (AKI) and unsure of the best fluid therapy method to prevent it? This clinical trial may contain important information.
Glucose 6 phosphate dehydrogenase deficiency (G6PDd) is the most common enzyme deficiency in humans. G6PD deficiency is a genetic condition that affects red blood cells and can lead to anemia and other complications. Heme-induced nephropathy (HIN) is a rare but serious complication that can occur when patients with G6PD deficiency receive intravenous heme-containing products, such as blood transfusions or certain medications.
HIN can lead to acute kidney injury and potentially permanent damage. There are several fluid therapies available to prevent acute kidney injury in G6PDd patients. However, strong clinical trials demonstrating their safety and effectiveness are lacking.
Clinical TrialA clinical trial explores the safety and effectiveness of normal saline fluid therapy for preventing hemolysis-related acute kidney injury in children with glucose 6 phosphate dehydrogenase (G6PD) deficiency.
The trial assessed the effectiveness of normal saline, a commonly used but least-examined fluid therapy method, in preventing HIN in children with G6PD deficiency.
It included 120 children with G6PD deficiency who were suffering from acute hemolysis. The children were randomly assigned to receive either normal saline, normal saline with sodium bicarbonate, or normal saline with acetazolamide. The frequency of AKI in these patients was measured.